NASDAQ:GRCL 延时15分钟已退市

成交量

Wei Cao: Wei Cao is the founder of Gracell Biotechnologies (Shanghai) Co., Ltd. (founded in 2017) and Gracell Biotechnologies, Inc. (founded in 2017). He is currently the Chief Executive Officer at Gracell Biotechnologies (HK) Ltd., Gracell Biopharmaceuticals, Inc., Suzhou Gracell Biotechnologies Co., Ltd., and Zephyrm Bioscience Ltd. (as an Independent Non-Executive Director starting in 2024). Dr. Cao previously worked as a Director at AbelZeta Pharma, Inc. from 2010 to 2016 and as the President, Chief Operating Officer & Director at Cellular Biomedicine Group Ltd. from 2010 to 2013. He holds a doctorate degree from Medical College of Virginia and Harvard Medical School, and an undergraduate degree from Zhongshan Hospital Fudan University.

Kevin Yili Xie: Yi Li Xie is the founder of Locust Walk Capital Management, which was founded in 2010. He was the Managing Partner from 2010 to 2014. Dr. Xie's current jobs include being a Director at PatientPoint, Inc. and the Chief Financial Officer at Gracell Biotechnologies, Inc. since 2020. Dr. Xie's former jobs include being the Managing Director at Great Point Partners LLC from 2005 to 2008, the Head-Healthcare Sector at Scopia Capital Management LP from 2009 to 2010, and the President at Fosun Healthcare Holdings from 2015 to 2020. Dr. Xie also served as an Independent Director at Alpha Healthcare Acquisition Corp., Luz Sa de SA, and Humanigen, Inc. from 2021 to 2023, 2019 to 2022, and 2021 to 2023, respectively. Additionally, Dr. Xie was a Director at ViewRay, Inc. from 2019 to 2022, the Chief Scientific Officer at Boehringer Ingelheim GmbH, and the Managing Director at Great Point Partners Private Equity in 2008. Dr. Xie's education includes an undergraduate degree from Tianjin University, a doctorate from City University of New York, and an MBA from The Wharton School of the University of Pennsylvania.

Gracie Tong: Gracie Tong currently works at Gracell Biotechnologies, Inc., as Investor Relations Contact.

Jenny Ni: Jenny Ni holds the position of Chief Technology Officer for Gracell Biotechnologies, Inc. In her past career Dr. Ni held the position of Head-Process Development at Pfizer Inc., Director-Developmental Sciences at VIRxSYS Corp. and Head-Process Development at Allogene Therapeutics, Inc. Jenny Ni received a doctorate from Kyoto University and a doctorate from Kunming Medical University.

Wendy Li: Wendy Li is currently the Chief Medical Officer at Gracell Biotechnologies, Inc. She previously worked as the Chief Medical Officer at EXUMA Biotech Corp. She obtained a doctorate degree from Sun Yat-Sen University.

亘喜生物